Ensysce Biosciences Acquires Signature Therapeutics for Undisclosed Sum

  • Feed Type
  • Date
    1/20/2016
  • Company Name
    Signature Therapeutics
  • Mailing Address
    1731 Embarcadero Road Palo Alto, CA 94303 USA
  • Company Description
    Signature Therapeutics creates value through our ability to efficiently advance relatively low risk drug discovery and development programs, which address large markets with clearly defined unmet needs.
  • Website
    http://www.signaturerx.com
  • Transaction Type
    M&A
  • Transaction Amount
    Undisclosed
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    Ensysce Biosciences and Signature Therapeutics are pleased to announce completion of a formal merger on Dec. 31, 2015, naming Dr. Lynn Kirkpatrick as CEO. The company will retain the name of Ensysce Biosciences and will be relocating to San Diego, California. Financial terms of the transaction were not disclosed.

Trending on Xconomy